Humana Inc. (NYSE:HUM – Get Rating) – Equities researchers at Oppenheimer decreased their Q4 2022 earnings per share (EPS) estimates for shares of Humana in a report released on Thursday, July 28th. Oppenheimer analyst M. Wiederhorn now expects that the insurance provider will earn $1.86 per share for the quarter, down from their prior estimate of $2.92. Oppenheimer has a “Outperform” rating and a $520.00 price target on the stock. The consensus estimate for Humana’s current full-year earnings is $24.65 per share.
Several other brokerages have also recently weighed in on HUM. Wells Fargo & Company raised their price target on shares of Humana from $512.00 to $514.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 25th. Loop Capital began coverage on Humana in a report on Thursday, June 16th. They issued a “buy” rating and a $510.00 price objective for the company. Credit Suisse Group set a $548.00 price objective on Humana in a report on Tuesday, July 19th. Sanford C. Bernstein began coverage on Humana in a report on Thursday, May 26th. They issued a “market perform” rating and a $506.00 price objective for the company. Finally, Barclays increased their price objective on Humana from $500.00 to $570.00 and gave the company a “maintains” rating in a report on Thursday. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Humana has a consensus rating of “Moderate Buy” and a consensus target price of $511.44.
Humana Price Performance
Humana (NYSE:HUM – Get Rating) last issued its quarterly earnings results on Wednesday, July 27th. The insurance provider reported $8.67 earnings per share for the quarter, topping the consensus estimate of $7.67 by $1.00. The company had revenue of $23.66 billion during the quarter, compared to analysts’ expectations of $23.44 billion. Humana had a net margin of 3.51% and a return on equity of 17.27%. The business’s quarterly revenue was up 14.6% on a year-over-year basis. During the same period last year, the business earned $6.89 EPS.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Humana by 15.2% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 61,164 shares of the insurance provider’s stock worth $28,469,000 after purchasing an additional 8,066 shares during the period. Riverview Trust Co bought a new position in Humana in the first quarter valued at about $32,000. Transcend Capital Advisors LLC grew its position in Humana by 18.3% in the first quarter. Transcend Capital Advisors LLC now owns 587 shares of the insurance provider’s stock valued at $255,000 after acquiring an additional 91 shares during the last quarter. CWM LLC bought a new position in Humana in the fourth quarter valued at about $218,000. Finally, CCLA Investment Management Ltd grew its position in Humana by 1.4% in the first quarter. CCLA Investment Management Ltd now owns 218,232 shares of the insurance provider’s stock valued at $95,075,000 after acquiring an additional 3,034 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.
Insider Transactions at Humana
In other news, insider Samir Deshpande sold 3,957 shares of Humana stock in a transaction on Tuesday, May 3rd. The stock was sold at an average price of $434.19, for a total transaction of $1,718,089.83. Following the completion of the sale, the insider now owns 5,529 shares of the company’s stock, valued at $2,400,636.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.39% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.